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Background: There has been no effective method to monitor the changes of blood coagulation after
thromboprophylaxis for elective arthroplasty patients. The objective of this study is to assess the coagulation
status of patients undergoing arthroplasty with thromboelastograph (TEG).
Methods: Ninety patients undergoing primary elective unilateral arthroplasty were investigated. Thromboprophylaxis
continued for at least 10 days. TEG was performed on the day before the operation and on postoperative days 1, 4,
and 9.
Results: The total hip and total knee groups showed significant changes in the distribution of different
hypercoagulable states on days 1–4 and on days 4–9. On day 9 after operation, 34 out of 90 (37.8%) of the total
hip and total knee patients were found with hypercoagulable state. Of these 34 patients with hypercoagulable
state, 26 (76.5%) demonstrated platelet or mixed hypercoagulability.
Conclusions: Thrombelastography was an effective way to identify hypercoagulability in patients undergoing
elective primary total knee and total hip replacement. Platelet may play an important role in the progress of
blood hypercoagulability.
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Venous thromboembolism (VTE), including pulmonary
embolism (PE) and deep vein thrombosis (DVT), is a severe
complication in major orthopedic surgery. The incidence of
venous thromboembolism following total joint replacement
(TJR) has diminished over the last three decades [1]. The
routine use of anticoagulants after total knee and total hip
replacement is strongly recommended by, at present, the
guidelines by the American Association of Chest Physicians
(ACCP) [2]. However, with the routine use of thrombopro-
phylaxis, some patients still develop DVT of the lower
extremity and PE, while a minority of them may be at* Correspondence: zhang.chi@zs-hospital.sh.cn
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unless otherwise stated.risk for bleeding complications [2-4]. This suggests that it
is important to accurately monitor the changes of coagula-
tion after anticoagulation during perioperative period.
Thromboelastograph (TEG) is a point-of-care test for
evaluation of hemostasis, which has been widely used in
the field of liver transplantation and coronary bypass
surgery as an intraoperative hemostatic monitoring device
[5-7]. By measuring the dynamic process of blood co-
agulation, with defined parameters reflecting integrity
of specific hemostatic components, this device can differ-
entiate hypercoagulable state into different types—platelet,
enzymatic, and mixed, according to the manufacturer [8].
But monitoring blood coagulation with thromboelasto-
graph had not gained popularity in the field of orthopedics
[9,10].
The objective of this study is to assess the coagulation
status of patients undergoing arthroplasty with TEG.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This study was conducted prospectively and approved by
the hospital’s ethics committee. Ninety patients (mean age
64 ± 2 years) undergoing primary elective unilateral total
knee or total hip replacement were investigated, with 48
patients for knee and 42 for hip. Informed consent was
obtained from each patient. The coagulation functions of
all patients were normal before operation. None of the pa-
tients has a history of heparin-induced thrombocytopenia
(HIT) or kidney insufficiency (CrCl < 30 ml/min).
All total knee and total hip replacements were performed
by the same group of surgeons, Genesis II knee system
of Smith & Nephew was used in the knee replacements,
Synergy hip system of Smith & Nephew, and Summit
hip system of Johnson & Johnson were used in the hip
replacements. All operations were performed under
general anesthesia. No transfusion of more than 2 units
of RBC within 6 h in perioperative period was done.
Fraxiparine, a type of low weight molecular heparin
(nadroparin calcium, 9,500 anti-Xa IU/mL), was used as
routine thromboprophylaxis after joint replacement. Single
daily doses of Fraxiparine were adjusted according to the
patient’s body weight as follows: 38 anti-Xa IU/kg adminis-
tered 12 h after surgery, 38 anti-Xa IU/kg re-administered
on a daily basis, up to and including postoperative day 3,
and 57 anti-Xa IU/kg administered since postoperative day
4. Thromboprophylaxis continued for at least 10 days.
TEG was performed on the day before the operation;
0.36 mL of whole blood was pipetted into a disposable
plastic cup within 4 min of blood sampling. A stationary
pin attached to a wire which can monitor movements isTable 1 The baseline characteristics of patients before operat
Total hip group Tota
n = 42
Age (years)
Mean ± SD 66.7 ± 9.7





Mean ± SD 163.2 ± 7.7 1
Min, max 150, 183
Weight (kg)
Mean ± SD 63.3 ± 9.9 6
Min, max 46, 82
BMI (kg/m2)
Mean ± SD 23.8 ± 3.2
Min, max 19.1, 32.5
P value was calculated by Chi-square test for category variable and one-way ANOVAimmersed into the sample. The cup oscillates back and
forth six times per minute. A computerized thromboe-
lastograph coagulation analyzer (TEG model 5000;
Haemoscope Corporation, Niles, IL, USA) was used in
this study. After the subcutaneous injection of nadroparin
sodium, TEG was performed at 4 h on postoperative days
1, 4, and 9.
TEG values include R (reaction time; time to initial
thrombus formation), K (rate of thrombus formation),
MA (maximum amplitude; thrombus strength), α-angle
(rate of thrombus formation), and CI (coagulation index).
CI is a computer-calculated linear combination of the R,
K, MA, and α-angle values, and reflects overall coagula-
tion status.
TEG-hypercoagulability was classified into three types:
(1) enzymatic hypercoagulability, CI > 3, R < = 5 min,
MA < = 70 mm; (2) platelet hypercoagulability, CI > 3,
R > 5 min, MA > 70 mm; (3) mixed hypercoagulability:
CI > 3, R < = 5 min, MA > 70 mm, according to the
manufacturer.
Statistical analysis
Data were presented as means ± standard deviation for
continuous variables with normal distribution and n (%)
for category variables. Student t test was used to compare
the means of continuous variable with normal distribu-
tion, and Chi-square test was used to compare the propor-
tion of category variable between the total hip group and
total knee group. Linear mixed model and estimating
equations (GEE) approach was used to analyze the re-
peated measurement of continuous data and categoricalion
l knee group Total P value
n = 48 n = 90
71.5 ± 7.6 69.2 ± 8.9 0.0104
54, 82 43, 82
7 (14.6) 20 (22.2) 0.0624
41 (85.4) 70 (77.8)
61.2 ± 7.7 162.2 ± 7.7 0.2427
150, 186 150, 186
5.1 ± 10.3 64.3 ± 10.1 0.4208
43, 89 43, 89
24.4 ± 3.4 24.6 ± 3.5 0.1074
18.9, 35.8 18.9, 35.8
for continuous variable.
Table 2 Effect of low molecular heparin prophylaxis on
the thrombelastography between the two patient groups
at different time points
Total hip group Total knee group Total P value
n = 42 n = 48 n = 90
R (mm)
Before 5.68 ± 0.92 5.86 ± 1.03 5.78 ± 0.98 0.4830
Day1 5.30 ± 1.04 5.63 ± 1.32 5.47 ± 1.20 0.1586
Day4 5.25 ± 0.98 5.56 ± 1.04 5.41 ± 1.02 0.1886
Day9 5.32 ± 1.12 5.68 ± 1.19 5.52 ± 1.17 0.1255
K (mm)
Before 1.90 ± 0.78 1.80 ± 0.39 1.85 ± 0.59 0.3866
Day1 1.61 ± 0.41 1.79 ± 0.54 1.71 ± 0.49 0.0847
Day4 1.35 ± 0.36 1.40 ± 0.34 1.38 ± 0.35 0.6934
Day9 1.30 ± 0.65 1.25 ± 0.35 1.28 ± 0.50 0.6763
MA (mm)
Before 61.15 ± 6.00 62.00 ± 5.34 61.63 ± 5.61 0.5607
Day1 63.20 ± 5.29 61.41 ± 4.50 62.27 ± 4.95 0.1658
Day4 66.81 ± 7.31 66.33 ± 6.23 66.55 ± 6.73 0.7103
Day9 69.35 ± 6.48 69.14 ± 6.84 69.24 ± 6.64 0.8783
α-angle
Before 67.76 ± 5.57 67.79 ± 5.17 67.78 ± 5.31 0.9784
Day1 69.13 ± 5.72 67.63 ± 6.64 68.34 ± 6.23 0.1844
Day4 72.15 ± 5.62 72.23 ± 3.85 72.19 ± 4.75 0.9450
Day9 74.06 ± 4.89 73.66 ± 4.65 73.84 ± 4.74 0.7273
CI
Before 0.42 ± 1.76 0.46 ± 1.34 0.44 ± 1.53 0.9251
Day1 1.12 ± 1.58 0.45 ± 1.89 0.77 ± 1.77 0.0455
Day4 1.94 ± 1.54 1.67 ± 1.26 1.80 ± 1.40 0.4236
Day9 2.23 ± 1.73 2.09 ± 1.52 2.15 ± 1.61 0.6695
Data are reported as mean ± SD.
Yang et al. Journal of Orthopaedic Surgery and Research 2014, 9:52 Page 3 of 6
http://www.josr-online.com/content/9/1/52data, respectively. The proportion of different kinds of hy-
percoagulability at four time points was compared using
Fisher’s exact test.
All statistical analysis was conducted using SAS 9.1.3
(SAS Institute Inc., Cary, NC, USA). P < 0.05 was regarded
as statistically significant.
Results
The characteristics of patients before operation were
shown in Table 1. The mean age of patients was 66.7
and 71.5 years for total hip group and total knee group,
respectively (P < 0.0166). The proportion of sex and means
of height, weight, and BMI between these two groups
were not statistically significant (P > 0.05).
1. Change of TEG between the two patients groups.
The differences in values of R, K, MA, α-angle, and
coagulation index (CI) between the two patient
groups were not statistically significant before
operation and on days 1, 4, and 9 after operation
(Table 2). There were no significant differences in
the response categories (normal, enzymatic, platelet,
and mixed hypercoagulability) between the total hip
group and total knee group (P = 0.0893).
2. Changes of hypercoagulable states. There were no
significant changes in the R, K, MA, α-angle, CI
before operation, and day 1 after operation. However,
significant change in the K, MA, α-angle, and CI was
observed on days 1–4 after operation. The changes in
the MA and α-angle were significant on days 4–9 after
operation (Figure 1).
The distribution of different hypercoagulable states
before and after operation in the total hip group and
total knee group were shown in Figure 2. As there were
no significant differences in the response categories
between the two patient groups, the pooled total hip
and total knee groups showed significant changes in
the distribution of different hypercoagulable states on
days 1–4 and on days 4–9 (Figure 2). On day 9 after
operation, 34 out of 90 (37.8%) of the total hip and total
knee patients were found with hypercoagulable state. Of
these 34 patients with hypercoagulable state, 26 (76.5%)
demonstrated platelet or mixed hypercoagulability.
Discussion
In patients undergoing elective total hip and total knee
arthroplasty, multiple factors disrupt the regulatory
mechanisms of hemostasis, such as endothelial injury,
stasis, and platelet activation [10-12]. These factors may
result in a hypercoagulable state. As we know, hyperco-
agulability has been implicated in the pathogenesis of
VTE events [9,10,12,13]. So both the AAOS and the
ACCP9 recommended to prevent VTE after electivejoint replacement [2,3]. But even with appropriate
thromboprophylaxis, a certain proportion of patients
still showed hypercoagulable tendency. Patel et al. con-
cluded in multicenter study that most VTE’s occurred
due to prophylaxis failure rather than failure to provide
prophylaxis [14].
Until now, there has been no effective method to ensure
adequate thromboprophylaxis with careful monitoring.
Because the curve of TEG reflects the different phases of
the clotting process and enables a qualitative evaluation
of the individual steps involved, recent studies suggested
that TEG could be used to identify hypercoagulable
state in a variety of clinical settings, and have revealed
an association between hypercoagulability measured by
thrombelastography and postoperative/postinterventional
thromboembolic complications [5,8-10,13]. Park et al.
reported that thromboelastography could be taken as a
better indicator of postinjury hypercoagulable state than
Figure 1 Proportion of different status of hypercoagulability at different time points.
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[15]. It was also suggested that evoked hypercoagulability
in the early postoperative period was important for pre-
dicting TE complications [16]. An observational study in
patients undergoing major noncardiac surgery found thatFigure 2 Trends of MA after operation between three groups. I
bars indicate the 95% confidence intervals. P value is the comparison
between different time points of the total hip and knee group.8 out of 95 (8.4%) of TEG-hypercoagulable patients had a
postoperative thromboembolic complication, while only 2
out of 145 (1.4%) of such patients experienced thrombo-
embolic episodes (P = 0.016) [17].
According to the classification of the TEG standard,
hypercoagulable patients fall into different types, including
enzymatic, platelet, and mixed hypercoagulability. Our
study found 38.1% total hip patients and 37.5% total knee
patients with hypercoagulable states on day 9 postopera-
tion. For most of these patients, their hypercoagulable
states could be classified into mixed hypercoagulability or
platelet hypercoagulability, which means MA values are
greater than 70 mm. MA is dependent on platelet concen-
tration, platelet function, and platelet-fibri interaction [6].
These findings indicated a marked increase in the platelet
factors related to the hypercoagulability while thrombo-
prophylaxis was performed with low weight molecular
heparin. Traditionally, endothelial injury and platelet
activation are known to be triggers for arterial throm-
boemboli. Arterial and venous thromboses have been
viewed as distinct conditions, with differences in risk
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evidence suggested that activation of platelets did indeed
contribute to the development and propagation of venous
thrombi [19]. Chirinos et al. reported that activation of
the endothelium, platelets, and leukocytes occurred in pa-
tients with VTE, and the formation of platelet-leukocyte
conjugates regulated leukocyte activation and participated
in linking thrombosis with inflammation in vivo [20]. In a
rabbit model of VTE, Takahashi et al. [21] demonstrated
that an antibody against von Willebrand factor (vWF)
(AJW200), which inhibited interactions between A1
domain and platelet GPIb, significantly reduced venous
thrombus formation and pulmonary thromboembolism.
These results suggest that VWF A1-platelet GPIb inter-
action played a significant role in venous thrombus for-
mation. Moreover, inhibition of P-selectin, a signaling
molecule exposed on the surface of an activated platelet,
which initiates inflammatory signaling pathways in under-
lying endothelium and recruits monocytes, resulted in
impaired thrombus formation both in an experimental
model of venous thrombosis and in vivo [22]. Thus, as
Gonzalez et al. [8] suggested, solely targeting final throm-
bin production by utilizing UH or LMWH may not pro-
vide enough protection against platelet activation, hence a
hypercoagulable state may persist.
Bozic et al. [23] found that patients who received aspirin
VTE prophylaxis had lower odds for thromboembolism
compared with warfarin patients but had similar odds
compared with those with injectable VTE prophylaxis.
ACCP9 recommended aspirin monotherapy as a method
for thromboprophylaxis after the joint arthroplasty. The
increase in MA values in our study confirmed that platelet
played an increasingly important role in the progress of
blood hypercoagulability.
It was also found in the current study that some patients
appeared to be enzymatic hypercoagulable after anticoa-
gulation. The simplest explanation for this would be that
the recommended dose of low molecular weight heparin
was insufficient. Since the exact effective dose of LMWH
for prophylaxis varies from patient to patient, it is neces-
sary to monitor the effects of the administered LMWH to
ensure that each individual patient is adequately anticoa-
gulated without bleeding tendency. TEG is a useful tech-
nique for rapid global assessment of hemostatic function
while the patient is receiving thromboprophylaxis after
joint arthroplasty. Since ACCP9 recommend the use of
pharmacologic thromboprophylaxis for a minimum of 10
to 14 days (Grade 1B), we believed that TEG data on post-
operation day 9 would be a potential measurement to
determine whether patients need extended prophylaxis or
not. However, lack of TEG data on day 35 was one limita-
tion of our study.
In conclusion, our results indicate that thrombelas-
tography was an effective way to identify hypo- andhypercoagulability in patients undergoing elective primary
total knee and total hip replacement. Under recommended
dose of LMWH, over 1/3 of patients were in hypercoagula-
bility on postoperative day 9. Furthermore, we found that
platelet may play an important role in the progress of blood
hypercoagulability.
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